Physician profile

Ali El Atat

Pulmonary Disease · Brooklyn, NY

NPI 1487853008

$482,281.18

in general payments reported to CMS, 2019-2025

50 companies · $124K in 2025

The $124K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$323,246.60
Food and Beverage$22,502.67
Travel and Lodging$9,692.30
Consulting Fee$6,045.00
Education$223.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $285,159.76 2019-2025 Fasenra, Breztri, Airsupra
Glaxosmithkline, LLC. $114,427.93 2019-2025 Arexvy, Trelegy Ellipta, Nucala
Regeneron Healthcare Solutions, INC. $38,583.70 2019-2025 Dupixent
Genzyme Corporation $19,532.77 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $8,625.30 2019-2025 Spiriva Respimat, Ofev, Jardiance
Bayer Healthcare Pharmaceuticals INC. $4,615.53 2019-2025
Genentech USA, INC. $1,942.64 2019-2025 Xolair
Actelion Pharmaceuticals US, INC. $1,299.67 2019-2025 Opsumit, Uptravi
Insmed, INC. $1,070.89 2019-2025 Arikayce, Brinsupri
Amgen INC. $815.44 2021-2025 Tezspire, Tavneos, Repatha
Janssen Pharmaceuticals, INC $703.40 2021-2024 Xarelto
Pfizer INC. $467.92 2019-2025
Lilly USA, LLC $397.74 2019-2025 Mounjaro, Zepbound
Mallinckrodt Hospital Products INC. $366.81 2021-2025 Acthar
Advanced Respiratory, INC $292.70 2019-2021
Show all 49 companies
CompanyGeneral paymentsYearsTop products
Verona Pharma, INC. $278.88 2025 Ohtuvayre
Paratek Pharmaceuticals, INC. $272.18 2023-2025 Nuzyra, Xhance
Biohaven Pharmaceutical Holding Company Ltd. $267.82 2022
Ani Pharmaceuticals, INC. $235.17 2023-2024 Purified Cortrophin Gel
Electromed, INC. $229.71 2019-2022
Inogen, INC. $218.69 2023-2024 Inogen One G5 Oxygen Concentrator - Bluetooth
Merck Sharp & Dohme LLC $199.76 2019-2023 Verquvo
United Therapeutics Corporation $189.99 2019-2025 Tyvaso, Tyvaso
Teva Pharmaceuticals USA, INC. $185.42 2019-2022
Philips North America LLC $173.66 2019-2020
Takeda Pharmaceuticals U.S.A., INC. $171.55 2022-2024 Aralast
Shield Therapeutics INC $165.77 2023-2025 Accrufer
Abbvie INC. $125.00 2025
Mylan Specialty L.P. $121.67 2022-2023 Yupelri
Ge Healthcare $104.19 2022
Novartis Pharmaceuticals Corporation $103.51 2020-2024
Sanofi-Aventis U.S. LLC $99.99 2025
Optinose US, INC. $95.22 2024-2025
Baxter Healthcare $83.18 2023-2024 Hillrom - Vest System Model 105 Home Care
Currax Pharmaceuticals LLC $78.46 2021-2022
Gilead Sciences, INC. $78.17 2019
Exact Sciences Corporation $78.00 2024 Cologuard Collection Kit
Novo Nordisk INC $77.74 2022-2024 Rybelsus, Ozempic
Circassia INC. $71.37 2019-2021
Biogen, INC. $57.24 2024-2025 Skyclarys
Esperion Therapeutics, INC. $43.66 2024-2025 Nexletol
Olympus America INC. $29.01 2020
Axsome Therapeutics, INC. $26.70 2023 Sunosi
Hikma Pharmaceuticals USA $20.98 2022
Inspire Medical Systems, INC. $20.85 2025 Inspire
Intra-Sana Laboratories $20.00 2024 Reltone 400 Mg, Reltone 200 Mg, Glycate
Itamar Medical INC $19.71 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $19.20 2024 Xifaxan
Horizon Therapeutics Plc $16.53 2020

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ali El Atat

$482,281.18

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals Lp
Context
The $124K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/832747/ali-el-atat

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.